Covaxin Phase-I human clinical trial begins at AIIMS, man given first dose: All you need to know
4 years, 5 months ago

Covaxin Phase-I human clinical trial begins at AIIMS, man given first dose: All you need to know

India TV News  

Countries across the world are in the race to develop a vaccine, and many of them, including India, are conducting human clinical trials to test the efficacy. The phase-I human clinical trial of Covaxin, India's first indigenously-developed vaccine against coronavirus, began at the All India Institute of Medical Sciences in Delhi today. COVAXIN HUMAN CLINICAL TRIALS AT AIIMS: PHASE 1 At least 375 volunteers will be administered the vaccine in Phase I. COVAXIN HUMAN CLINICAL TRIALS AT AIIMS: PHASE II The second phase will have around 750 volunteers from all 12 sites together. A RECAP Covaxin Phase-I human clinical trial begins at AIIMS First Covaxin dose given to a man in his 30s No side effects of Covaxin observed so far

India Delhi Trial Man Human Phase Rai Vaccine Given Clinical Aiims Dose Covaxin Human Clinical Trials First Dose  trial  man  human  dose  covaxin  aiims  trials  volunteers  vaccine  know  given  clinical  phase  need  phasei

History of this topic

The right way to counter a poor Covaxin safety study
4 months, 3 weeks ago

The right way to counter a poor Covaxin safety study

The Hindu  

It took all of five days for the Indian Council of Medical Research to strongly criticise the poor design of the long-term safety study of Covaxin by researchers from the Banaras Hindu University, Varanasi. A publication failure that is glaring Three years after the interim data were posted as a preprint, Bharat Biotech and ICMR are yet to publish any …

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
7 months, 3 weeks ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

Serum Institute of India to produce 5mn Covishield doses in two months
1 year, 8 months ago

Serum Institute of India to produce 5mn Covishield doses in two months

Hindustan Times  

Serum Institute of India chief executive officer Adar Poonawalla, while underlining that the current strain of Covid is mild and the demand for vaccine shots is low, said his firm will produce five to six million Covishield doses in the next two to three months and same amount of stock is already available for Covovax. According to Poonawalla, SII has …

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch
1 year, 11 months ago

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch

Hindustan Times  

Around 250 million Covid vaccines manufactured by two major Hyderabad-based units – Biological E and Bharat Biotech – are ready for dispatch in the market as soon as orders are received. Nearly 200 million Corbevax vaccine of Biological E and 50 million of Bharat Biotech's Covaxin are stockpiled at the moment. Read| Covid drills at hospitals; case count remains low …

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
1 year, 11 months ago

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

India TV News  

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. Corbevax and Covaxin stocks Biological E held 200 million doses of its …

Bharat Biotech misstated Covaxin trial data
2 years ago

Bharat Biotech misstated Covaxin trial data

Deccan Chronicle  

HYDERABAD: Extremely serious procedural leniencies and incorrect reporting of the results of trials of Covaxin, Bharat Biotech’s anti-Covid vaccine, have come to light, raising some very uncomfortable questions on the vaccine’s rollout for general use in India. Inquiries and investigation into the three phases of human trials of Covaxin have found grave reporting errors – some that appear to be …

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take
2 years, 1 month ago

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take

India TV News  

Highlights Covaxin lying with the firm are set to expire early next year There are no takers owing to poor demand, said company sources India reported 1,082 fresh COVID-19 cases on Saturday Covaxin news: Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers …

Corbevax as Covid booster for adults from August 12. Check details
2 years, 4 months ago

Corbevax as Covid booster for adults from August 12. Check details

India Today  

In a boost to India’s fight against coronavirus, the government gave nod to Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Announcing the decision, Union Health minister Mansukh Mandaviya said, “Further Strengthening India's arsenal against Covid-19, Ministry of Health and Family Welfare approves Corbevax as precaution dose for those …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 4 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 4 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

India TV News  

Highlights Biological E's Corbevax has been approved as a booster or precaution dose. Covid vaccination: Biological E's Corbevax has been approved as a booster or precaution dose for those above the age of 18, and those who are fully vaccinated with either Covishield or Covaxin. "Corbevax will be considered as a precaution dose after completion of six months or 26 …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 4 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 4 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

PM Modi hails India\'s 200 crore COVID vaccination feat
2 years, 5 months ago

PM Modi hails India\'s 200 crore COVID vaccination feat

Deccan Chronicle  

New Delhi: India crossed the milestone of administering 200 crore Covid-19 vaccine doses at around Sunday noon, almost one-and-a-half years after starting the drive in January 2021. The administration of 200 crore doses includes 101.9 crore doses as the first jab, while 92.6 crore doses as the second and 5.49 crore as precaution dose. As many as 71 per cent …

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership
2 years, 5 months ago

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership

News 18  

India has crossed record 200 crore mark in Covid-19 vaccinations within 18 months of launching the inoculation exercise in January last year. #200CroreVaccinations https://t.co/FtobFYBprV— Dr Mansukh Mandaviya July 17, 2022 A seven-phase vaccination drive was followed on the principle of Prioritization for Vaccine Administration based on scientific advice and global best practices, government officials told News18. While some experts had …

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech
2 years, 6 months ago

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech

The Hindu  

Bharat Biotech International Limited, on Friday, announced that COVID-vaccine Covaxin has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study. The company in its press release said that Bharat Biotech had conducted phase II/III, open-label, and multi-centre study to evaluate the safety, reactogenicity, and immunogenicity Covaxin in healthy children and adolescents in 2-18 years …

ICMR Study Has Shown Rise in Antibodies Post Covaxin Booster Dose: MoS Health Tells Rajya Sabha
2 years, 8 months ago

ICMR Study Has Shown Rise in Antibodies Post Covaxin Booster Dose: MoS Health Tells Rajya Sabha

News 18  

An ICMR study to examine the effect of Covaxin's booster dose has shown an increase in the levels of antibodies against SARS-CoV-2, Minister of State for Health Bharati Pravin Pawar told the Rajya Sabha on Tuesday. International data available on booster doses of AstraZeneca and Covishield suggests a three- to four-fold increase in antibody levels after their administration, Pawar said …

Why India's vaccine advisory body recommends reducing second-dose gap for Covishield
2 years, 9 months ago

Why India's vaccine advisory body recommends reducing second-dose gap for Covishield

Firstpost  

The National Technical Advisory Group on Immunisation has recommended that the gap between the first and second dose of Covishield should be reduced to eight to 16 weeks, from the current gap of 12 to 16 The National Technical Advisory Group on Immunisation has recommended that the gap between the first and second dose of Covishield should be reduced to …

2nd Covishield Dose Can Now Be Taken Between 8-16 Weeks After 1st Dose, No Word on Covaxin Yet
2 years, 9 months ago

2nd Covishield Dose Can Now Be Taken Between 8-16 Weeks After 1st Dose, No Word on Covaxin Yet

News 18  

The National Technical Advisory Group on Immunisation has recommended administering the second dose of Covid-19 vaccine Covishield between eight and 16 weeks after the first dose, officials said on Sunday. Under the National Covid-19 Vaccination Strategy, the second dose of Covishield is to be given between 12-16 weeks after the first dose. An official source said the latest recommendation of …

COVID: India's vaccination coverage crosses 180 crore landmark
2 years, 9 months ago

COVID: India's vaccination coverage crosses 180 crore landmark

India TV News  

Highlights India's COVID-19 vaccination coverage crossed 180 crore landmark milestone on March 12 Over 2.12 cr Precaution Doses for identified categories of beneficiaries have also been administered Dr Mansukh Mandaviya congratulated the nation on achieving this historic landmark With the administration of more than 17 lakh vaccine doses, India's COVID-19 vaccination coverage crossed 180 crore landmark milestone on Saturday, informed …

COVID: Over 2 crore precaution doses administered among eligible beneficiaries, says Mansukh Mandaviya
2 years, 9 months ago

COVID: Over 2 crore precaution doses administered among eligible beneficiaries, says Mansukh Mandaviya

India TV News  

Highlights India has so far administered over 2 cr precaution doses among the eligible beneficiaries Over 97% of India's adult population have also received their 1st dose of vaccine against COVID Health Min Mansukh Mandaviya requested eligible beneficiaries to get their 3rd shot at the earliest India has so far administered over 2 crore precaution doses or the third vaccine …

Beneficiaries in 15-18 years age group to start getting second dose of COVID-19 vaccine from today
2 years, 10 months ago

Beneficiaries in 15-18 years age group to start getting second dose of COVID-19 vaccine from today

Firstpost  

Covaxin is the only vaccine option for the 15-18-year age group, according to health ministry guidelines on 27 December, 2021 New Delhi: Beneficiaries in the age group of 15 to 18 years will start receiving their second dose of COVID-19 vaccine from Monday, officials said. Delhi has around 10.14 lakh beneficiaries in the age group. Covaxin is the only vaccine …

Bharat Biotech gets approval for intranasal Covid-19 booster dose trials
2 years, 10 months ago

Bharat Biotech gets approval for intranasal Covid-19 booster dose trials

India TV News  

Highlights Intranasal vaccine will be administered to those who have already taken their two-dose vaccine The interval between the second dose of Covid vaccine and booster dose will be six months According to Bharat Biotech, its nasal vaccine stimulates immune responses at the site of infection The Drugs Controller General of India has granted permission to Hyderabad-based biotechnology firm Bharat …

Two COVID vaccines may cost Rs. 275 after market nod
2 years, 10 months ago

Two COVID vaccines may cost Rs. 275 after market nod

Deccan Chronicle  

NEW DELHI: In a bid to make vaccines against Covid-19 affordable, prices of Covishield and Covaxin jabs are likely to be capped at Rs 275 per dose, with an additional service charge of Rs 150. Serum Institute of India director Prakash Kumar Singh had submitted an application to the DCGI on October 25 seeking regular market approval for its Covishield …

SEC recommends Covaxin, Covishield for full market authorisation: Report
2 years, 11 months ago

SEC recommends Covaxin, Covishield for full market authorisation: Report

Hindustan Times  

The subject expert committee of the Central Drugs Standard Control Organisation on Wednesday recommended regular market approval for Covaxin and Covishield, the two most widely used jabs in the national vaccination drive against Covid-19, news agency PTI has reported, citing official sources. The development comes just days after the SEC, on January 14, sought more data from the two manufacturers--Hyderabad-based …

Bharat Biotech again urges health workers to be ‘highly vigilant’ while jabbing teenagers
2 years, 11 months ago

Bharat Biotech again urges health workers to be ‘highly vigilant’ while jabbing teenagers

Hindustan Times  

Hyderabad-based Bharat Biotech International Limited on Tuesday urged healthcare workers to be ‘highly vigilant’ while administering jabs to teenagers aged 15 to 18, citing what it said were ‘additional reports’ stating that beneficiaries in the said age group were being jabbed with ‘unapproved Covid-19 vaccines.’ A medic administers Covid vaccine to a teen in Ludhiana at the civil surgeon’s office. …

Covaxin booster shot neutralises Omicron, says Bharat Biotech
2 years, 11 months ago

Covaxin booster shot neutralises Omicron, says Bharat Biotech

Hindustan Times  

India's vaccine-maker Bharat Biotech on Wednesday said that a booster dose of its Covid-19 vaccine ‘Covaxin’ neutralises both the Omicron and Delta variants of the coronavirus. The study, "The neutralisation activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant," Reuters quoted Bharat Biotech as saying in a statement. Citing the …

India begins new vaccine phase in COVID-19 fight, ‘precautionary doses’ for frontline workers and seniors from today: All you need to know
2 years, 11 months ago

India begins new vaccine phase in COVID-19 fight, ‘precautionary doses’ for frontline workers and seniors from today: All you need to know

Firstpost  

An estimated 1.05 crore healthcare and 1.9 crore frontline workers, and 2.75 crore co-morbid people in the 60-plus age group would be administered the third dose of the COVID-19 vaccine The country will begin a new phase in its fight against coronavirus, as it will start administering a third COVID-19 precautionary dose to healthcare and frontline workers, and those over …

Holds promise: ICMR on trial results of third dose of Covaxin
2 years, 11 months ago

Holds promise: ICMR on trial results of third dose of Covaxin

Hindustan Times  

A day after Bharat Biotech released the trial results of the safety and immunogenicity of its Covid-19 vaccine ‘Covaxin’ as a booster shot, the Indian Council of Medical Research on Sunday affirmed the findings. Prime Minister Narendra Modi, in a televised address on December 25, 2021, announced precaution doses for healthcare and frontline workers from January 10 and Covid-19 jabs …

Covaxin booster shot may provide long-term immunity against severe Covid, says Bharat Biotech
2 years, 11 months ago

Covaxin booster shot may provide long-term immunity against severe Covid, says Bharat Biotech

India Today  

A booster dose of Bharat Biotech's Covid-19 vaccine Covaxin, administered six months after the second dose, could provide long-term immunity from severe SARS-CoV-2 infection, a study by Bharat Biotech and the Indian Council of Medical Research - National Institute of Virology, Pune, has indicated. The study, published on medRxiv and not yet peer-reviewed, said that the Covaxin booster shot is …

SEC approval for Bharat Biotech\'s COVID booster intranasal vaccine phase 3 trials
2 years, 11 months ago

SEC approval for Bharat Biotech\'s COVID booster intranasal vaccine phase 3 trials

Deccan Chronicle  

New Delhi: The Subject Experts Committee of the Drug Controller General of India on Wednesday granted approval to Bharat Biotech for conducting intranasal phase 3 trials and heterologous trials for COVID-19 booster intranasal vaccine for those who have taken both the doses of Covaxin and Covishield. "After detailed deliberation, the SEC 'in principle' agreed for the conduct of both phase …

SEC Recommends Bharat Biotech to Conduct Late-stage Trials, Submit Booster Protocol
2 years, 11 months ago

SEC Recommends Bharat Biotech to Conduct Late-stage Trials, Submit Booster Protocol

News 18  

The Subject Expert Committee of India’s drug authority has recommended Bharat Biotech to conduct late-stage trials for its intranasal vaccine BBV154. After discussions and deliberations for almost five hours on Tuesday, the expert panel has asked Bharat Biotech to add a Covishield arm in the booster trails and submit a protocol for the same. Bharat Biotech will submit a revised …

SEC Meet to Discuss Bharat Biotech’s Nasal Vaccine as Booster for Those Jabbed with Covishield, Covaxin
2 years, 11 months ago

SEC Meet to Discuss Bharat Biotech’s Nasal Vaccine as Booster for Those Jabbed with Covishield, Covaxin

News 18  

The Subject Expert Committee of India’s drug authority is set to meet to examine Bharat Biotech’s application for its intranasal Covid vaccine as a booster or a third dose, CNN-News18 has learnt. In its application, the company has proposed to use its intranasal vaccine BBV154 as a heterologous booster dose in already vaccinated individuals, who have received two doses of …

AP teenagers to start getting jabs from today
2 years, 11 months ago

AP teenagers to start getting jabs from today

Deccan Chronicle  

VIIJAYAWADA: Teenagers in the 15-18 years age-group will start getting Covid vaccination doses across the state from Monday. She said booster doses would be given to healthcare and frontline workers who had taken the second dose at least 39 weeks before January 10. Health and family welfare state commissioner Katamneni Bhaskar said that nearly 19 lakh ANMs would administer the …

India Sending 1 Million Covaxin Doses to Afghanistan for First Time after Taliban Takeover - News18
2 years, 11 months ago

India Sending 1 Million Covaxin Doses to Afghanistan for First Time after Taliban Takeover - News18

News 18  

India is providing 1 million doses of its indigenous Covid-19 vaccine, Covaxin, produced by Hyderabad-based Bharat Biotech, to Taliban-controlled Afghanistan, a top government official privy to the development told CNN-News18. The first shipment consisting of 5 lakh doses of Covaxin has been sent by Mahan airways and would reach Afghanistan’s capital Kabul on Saturday. The Covaxin doses are being sent …

\'Precaution dose\' vaccine: NTAGI to decide next week
2 years, 11 months ago

\'Precaution dose\' vaccine: NTAGI to decide next week

Deccan Chronicle  

New Delhi: Amid a sharp rise in Covid-19 cases across the country, the National Technical Advisory Group on Immunisation and its working group will meet next week to finalise which vaccine will be given as a “precautionary” dose to healthcare and frontline workers and senior citizens above 60 with co-morbidities from January 10. The order issued by DCP S. Chaitanya …

Bharat Biotech Seeks DCGI Nod for Trials to Evaluate Efficacy of Covaxin Booster Shot - News18
2 years, 11 months ago

Bharat Biotech Seeks DCGI Nod for Trials to Evaluate Efficacy of Covaxin Booster Shot - News18

News 18  

Bharat Biotech has sought permission from India’s drug regulator to conduct clinical trials for evaluating the efficacy of a third dose of its Covid-19 vaccine, Covaxin. According to a top government official, the indigenous vaccine maker has proposed to conduct clinical trials for Covaxin’s booster shot on 5,000 healthy volunteers, keeping a gap of six months between the second and …

Covaxin cleared for those above 12
2 years, 11 months ago

Covaxin cleared for those above 12

The Hindu  

Covaxin has been approved for use in those aged 12 and above by the Drugs Controller General of India. The DCGI in August granted emergency approval to Zycov-D, a three-dose, DNA COVID-19 vaccine developed by the Ahmedabad-based Zydus Cadilla Group, making it the first vaccine in India that could be administered to adults and those 12 and above. Welcoming the …

Bharat Biotech's Covaxin gets DCGI nod for emergency use for children aged 12-18
2 years, 11 months ago

Bharat Biotech's Covaxin gets DCGI nod for emergency use for children aged 12-18

Firstpost  

With this, Covaxin becomes the second COVID-19 vaccine cleared for use for children in India. In August, Zydus Cadila’s three-dose DNA jab was allowed to be used on all over the age of 12 Bharat Biotech’s Covaxin, India’s indigenous COVID-19 vaccine, received approval from drug regulator DCGI for emergency use for children aged between 12-18 years on Saturday. Bharat Biotech …

Bharat Biotech to donate 2 lakh doses of covaxin to Vietnam
3 years ago

Bharat Biotech to donate 2 lakh doses of covaxin to Vietnam

Live Mint  

Bharat Biotech will donate 2,00,000 doses of covaxin to The Republic of Vietnam, the Hyderabad based pharmaceutical company said on Thursday. This donation represents a gesture of goodwill to provide access to Bharat Biotech World Health Organization approved, indigenously developed covaxin to fight the covid-19 pandemic across borders, Suchitra Ella, Joint Managing Director of Bharat Biotech said. Bharat Biotech was …

Covaxin shows 50% effectiveness against symptomatic Covid-19, says Lancet study
3 years, 1 month ago

Covaxin shows 50% effectiveness against symptomatic Covid-19, says Lancet study

India Today  

Two doses of Covaxin are 50 per cent effective against the symptomatic disease, according to the first real-world assessment of India's indigenous Covid-19 vaccine published in The Lancet Infectious Diseases journal. Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and …

How Macaulay Putras Ridiculed Covaxin and Data Proved Them Wrong
3 years, 1 month ago

How Macaulay Putras Ridiculed Covaxin and Data Proved Them Wrong

News 18  

The Phase III human clinical trials of Covaxin began in mid-November 2020, involving 26,000 volunteers, between 18 and 98 years of age, across 21 sites. It was India’s first and only Phase III study for a COVID-19 vaccine, and the largest Phase III efficacy trial ever conducted here for any vaccine. He said that if the East India Company had …

Vaccine Hesitancy Greatest Threat in Overcoming Covid: Adar Poonawalla
3 years, 1 month ago

Vaccine Hesitancy Greatest Threat in Overcoming Covid: Adar Poonawalla

News 18  

Serum Institute of India CEO Adar Poonawalla on Wednesday termed vaccine hesitancy as the greatest threat in overcoming the COVID-19 pandemic while urging all adults to get vaccinated at the earliest. He said that 200 million doses of the COVID-19 vaccine were lying with the states and people should get themselves vaccinated as soon as possible. Vaccine hesitancy is now …

Bharat Biotech's Covaxin phase 3 data shows 77.8 pc efficacy against COVID, says Lancet
3 years, 1 month ago

Bharat Biotech's Covaxin phase 3 data shows 77.8 pc efficacy against COVID, says Lancet

India TV News  

Hyderabad-based Bharat Biotech on Friday announced that the Lancet peer-review confirmed the efficacy analysis of Bharat Biotech's Covaxin. "COVAXIN is the only COVID-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the delta variant at 65.2 per cent," the official statement issued by Bharat Biotech said citing the study by the Lancet. "Efficacy analysis demonstrates Covaxin …

Covaxin 77.8% Effective Against Covid-19, 65.2% Against Delta Variant: Lancet Study
3 years, 1 month ago

Covaxin 77.8% Effective Against Covid-19, 65.2% Against Delta Variant: Lancet Study

News 18  

Covaxin, a Covid-19 vaccine developed by Hyderabad-based Bharat Biotech, was found to have a 77.8% efficacy rate against symptomatic Covid-19, as per an analysis published in The Lancet. The roll-out of Covaxin can “increase the finite global manufacturing capacity, and improve the insufficient supply of vaccines which disproportionately affects low-income and middle-income countries”, said Chinese researchers Li Jingxin Li and …

Covaxin Maker Bats for Booster Shots in India, Says Ideal After 6 Months of 2nd Dose
3 years, 1 month ago

Covaxin Maker Bats for Booster Shots in India, Says Ideal After 6 Months of 2nd Dose

News 18  

After several countries have begun inoculating the vulnerable population with booster shots against Covid-19, Covaxin manufacturer- Bharat Biotech CMD Krishna Ella said that a booster dose would be ideal six months after receiving the second dose of the anti-Covid vaccine. Taking about the delay in granting the EUA by the World Health Organisation for Covaxin, Ella blamed the “negative campaign” …

Covaxin gets WHO’s emergency use nod
3 years, 1 month ago

Covaxin gets WHO’s emergency use nod

The Hindu  

India’s first indigenous COVID-19 vaccine, Bharat Biotech’s Covaxin, was granted Emergency Use Listing by the World Health Organization on Wednesday. Union Health Minister Mansukh Mandaviya, welcoming the announcement, said, “This is a proud moment for the entire country.” The WHO in its tweets on Wednesday said that the Technical Advisory Group, convened by the WHO and made up of regulatory …

Second dose of Covid vaccine overdue for over 11 crore people: Govt data
3 years, 1 month ago

Second dose of Covid vaccine overdue for over 11 crore people: Govt data

Live Mint  

Over 11 crore people who have taken the first shot of COVID-19 vaccine have not got themselves jabbed with the second dose even after the expiry of the prescribed interval between two doses, according to government data. The data showed that over 3.92 crore beneficiaries are more than six weeks overdue for their second dose, around 1.57 crore are up …

Covaxin Granted EUL by WHO: Tracing The COVID-19 Vaccine's Journey
3 years, 1 month ago

Covaxin Granted EUL by WHO: Tracing The COVID-19 Vaccine's Journey

The Quint  

On 7 December Bharat Biotech officially applied for Emergency Use Authorisation for Covaxin. On 9 December, However, the DGCI asked Bharat biotech to submit more data for Covaxin before it could be granted an EUA. On 2 January 2021, Covaxin received EUA from the DGCI for restricted use "in public interest as an abundant precaution, in clinical trial mode, specially …

No Nod for Covaxin Yet as WHO Seeks More Data, Final Assessment Likely on November 3
3 years, 1 month ago

No Nod for Covaxin Yet as WHO Seeks More Data, Final Assessment Likely on November 3

News 18  

The World Health Organization on Tuesday once again postponed granting approval to India’s indigenous Covid-19 vaccine Covaxin, seeking more technical details to conduct a final ‘risk-benefit assessment’. The global body — which was reviewing data on India’s Covaxin shot against Covid-19 to grant Emergency Use Listing — has sought additional information from Hyderabad-based Bharat Biotech to conduct a final “risk-benefit …

Discover Related